Gokhan YAPRAK, Naciye IŞIK, Ozlem Yetmen DOGAN, Fatih DEMİRCİOGLU, Emriye ALGUL, Beyhan CEYLANER BICAKCI, Hazan ÖZYURT

Re-irradiation results of fractionated stereotactic radiotherapy (FSRT) with cyberknife for locally-advanced nasopharengeal carcinoma (NPC)

Aim: Recurrent nasopharyngeal carcinoma (NPC) after previous radiation therapy is a major problem. This study was conducted to determine the survival benefits and potential benefits of the effects of severe late toxicities by re-irradiation with fractionated stereotactic radiotherapy (FSRT).Material and Methods: 2009-2018, treatment outcomes were evaluated retrospectively in 26 patients with local recurrent NPC were cured applying FSRT with Cyberknife. Five patients had metastatic disease and one had second recurrence was excluded from the research, remaining 20 patients were analyzed. Median agewas 52 years (range,28-80 years), re-treatment T stagewas; 6 (30%) T2, 5 (25%) T3, 9 (45%) T4.Median time from initial RT to recurrence was 22 months (range,8-159 mo.). The median re-irradiation FSRTdose was 30Gy in 5 fractions.Results: Median follow-up was44 (22-179)months, the overall survival(OS) rate, local failure-free survival (LFFS ) and disease progression-free survival(DPFS) rate at 3 years were 89%,73% and 53%, respectively. All patients were evaluated for response after treatment; 9 (45%) had complete, 3 (15%) partial, 6 (%30) had no response.Univariate analysis demonstrated that; higher cumulativetotal radiotherapy dose, gross tumor volume and recurrent time interval were prognostic factors for LFFS. Recurrent time interval was also independent factor for DPFS and OS. The incidence of temporal lobe necrosis and trismus were 10% and 20%,respectively. One patient had grade 5 toxicity to treatment related bleeding.Conclusion: Tumor dose coverage is critical for treating recurrent NPC and treatment linked death rate was vascular in nature. Fractionated stereotactic radiotherapy is promising treatment modality for recurrent NPC.

PDF

___

1. Lee N, Xia P, Quivey JM, , et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol BiolPhys 2002;53:12-22.
2. Peng G, Wang T, Yang KY, et al.A prospective, randomized study comparing out comes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104:286-93.
3. Lee N, Harris J, Garden AS,et al. . Intensity-modulated radiation therapy with or with out chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.J Clin Oncol 2009;27:3684-90.
4. Han F, Zhao C, Huang SM, et al. Long-term out comes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensitymodulated radiotherapy. Clin Oncol (R CollRadiol) 2012;24:569-76.
5. Hua YJ, Han F, Lu LX, et al. Long-term treatment out come of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer 2012;48: 3422-8.
6. Qiu S, Lin S, Tham IW,et al. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;83:676-83.
7. Yamazaki H ,Demizu Y, Okimoto T, et al. Comparison of re-irradiation outcomes for charged particle radiotherapy and robotic stereotactic radiotherapy using cyberknife for recurrent head and neck cancers: a multi-institutional matched-cohort analysis. Anticancer Res 2016;36:5507-14 .
8. Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 2014;113: 364-70.
9. Morimoto K, Demizu Y, Hashimoto N, et al. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skullbase invasion. Jpn J Clin Oncol 2014;44: 428-34.
10. Demizu Y, Fujii O, Terashima K, et al. Particle therapy for mucosal melanoma of the head and neck. A single institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 2014;190: 186-91.
11. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
12. Chua DT, Sham JS, Kwong DL, et al. Locally recurrent nasopharyngeal carcinoma: treatment results for patients with computed tomography assessment. Int J Radiat Oncol Biol Phys 1998;41:379-86
13. Leung TW, Tung SY, Sze WK, et al. Salvage radiationtherapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:1331- 8.
14. Taussky D, Dulguerov P, Allal AS. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. HeadNeck 2005;27:182-6.
15. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J ClinOncol 1992;10:1245-51.
16. Forastiere AA, Leong T, Rowinsky E, et al... Phase III comparison of high-dosepaclitaxel + cisplatin + granulocyte colony stimulating factor versus lowdose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J ClinOncol 2001;19:1088-95.
17. Gibson MK, Li Y, Murphy B, et al.; EasternCooperativeOncologyGroup. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An inter group trial of the Eastern Cooperative Oncology Group. J ClinOncol 2005;23:3562-7.
18. Koutcher L,LeeN,Zelefsky M, et al.. Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy .Int J Radiat Oncol BiolPhys 2010;76,130-7.
19. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004;60:1440-50.
20. Teo PM, Leung SF, Tung SY, et al. Dose–response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). RadiotherOncol 2006;79:27-33.
21. Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma. Treatment techniques and results. Int J Radiat Oncol BiolPhys 1987;13:953-6. 22. 22- Öksüz DÇ, Meral G, Uzel Ö,et al. Reirradiation for locally recurrent nasopharyngeal carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2004; 60:388-394.
23. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. RadiotherOncol 2000;54:135-42.
24. Chua DT, Sham JS, Leung LH, et al. Reirradiation of nasopharyngeal carcinoma with intensitymodulatedradiotherapy.RadiotherOncol2005; 77:290- 294.
25. Chua DT, Sham JS, Kwong PW, et al. Linear acceleratorbased stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 2003;56:177-83.
26. Low JS, Chua ET, Gao F, et al. Stereotactic radiosurgery plus intracavitary irradiation in the salvage of nasopharyngeal carcinoma. Head Neck 2006;28:321- 9.
27. Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:761-9.
28. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25:953-64.
29. Kong L, Hu J, Guan X, et al. Phase I/II trial evaluating carbon ion radiotherapy for salvaging treatment of locally recurrent nasopharyngeal carcinoma. J Cancer 2016;7:774-83.
30. F. Dionisia, S. Crocib, I. Giacomellia, et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. ActaOncologıca 2019: 58:9:1238-45.
31. Kwong DL, Wei WI, ChengAC, et al. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma. Cancer 2001;91:110-13.
32. Ahn YC, Lee KC, Kim DY, et al. Fractionated stereotactic radiation therapy for extracranial head and neck tumors. Int J RadiatOncolBiolPhys 2000;48:501-5.
33. Kong L, Lu JJ.Reirradiation of locally recurrent nasopharengeal cancer. History, advances and promises for the future.ChinClinOncol 2016;5-26.
34. Sze WM, Lee AW, Yau TK, et al. Primary tumor volume of nasopharyngeal carcinoma: Prognostic significance for local control. Int J Radiat Oncol Biol Phys 2004;59:21-7.
35. Yue Q, Zhang M, Chen Y, et al. .Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensitymodulated radiotherapy: A meta-analysis. Oral Oncol 2018;81:81-8.
36. Chua DT, Wu SX, Lee V, et al.Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: A matched-cohort analysis. Head Neck Oncol 2009;1:13.
37. Pai PC, Chuang CC, Wei KC, et al. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. HeadNeck 2002;24:748-53.
38. Xiao JP, Xu GZ, Miao YJ .Fractionated stereotactic radiosurgery for 50 patients with recurrent or residual nasopharyngeal carcinoma .Int J RadiatBiol Phys 2001;51:164-70.
39. Sato H, Niimi A, Yasuhara T, et al.. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017;8:1751.